IHC testing is the basis for classification of four main BC subtypes: luminal A (LA), luminal B (LB), human epidermal growth factor receptor 2 positive (HER2+) and triple negative (TNBC, so called basal breast cancer). This evidence concerns the gene ERBB2 and breast carcinoma.